Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:07:37.470Z.
Consensus retrieved: 2026-10-06T13:40:36.457Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:07:37.470Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
Forward PE Ratio (N/A) = Dated Quote Price ($3.30) / Consensus Forward EPS ($-1.19)
FORWARD PE RATIO
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$259.12M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $259.12M | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | N/A |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A |
| AC Immune S.A. (ACIU)vs › | $256.47M | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 18.21 |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.30, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.19 | $-1.31 – $-1.00 | 7 | n/m |
| 2027-12-31 | $-1.34 | $-1.61 – $-1.07 | 7 | n/m |
| 2028-12-31 | $-1.20 | $-1.79 – $-0.75 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
